Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986325 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort J1 | EXPERIMENTAL | - |
| Cohort J2 | EXPERIMENTAL | - |
| Cohort J3 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986325 | DRUG | Specified dose on specified days |
| Placebo | DRUG | Specified dose on specified days |
Inclusion Criteria: * Participants must be ethnically Japanese (both biological parents are ethnically Japanese). * Healthy male and female participants as determined by no clinically significant deviation from normal in medical history, physical examination, 12-lead ECGs, or clinical laboratory de...
BMS-986325 is an investigational small molecule drug being developed by Bristol-Myers Squibb Company. It is in Phase 1 clinical development, and the specific diseases or conditions it is intended to treat have not been disclosed. It has been studied in healthy volunteers rather than in patients with a named disease.
BMS-986325 is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. The company sponsored the Phase 1 study of the compound conducted in the United States.
BMS-986325 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The compound is investigational and has not been approved by the FDA for any indication.
BMS-986325 has been evaluated in one completed Phase 1 trial, NCT05813717, titled A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986325 in Healthy Japanese Participants. The trial enrolled 25 healthy volunteers in the United States and used a randomized, double-blind, controlled design.
The Phase 1 trial NCT05813717 evaluated the safety, tolerability, drug levels, and drug effects of BMS-986325 in healthy Japanese participants. It enrolled 25 healthy volunteers aged 18 years and older in the United States and was randomized, double-blind, and controlled. The study has been completed.